Your browser doesn't support javascript.
loading
The genomic and epigenomic evolutionary history of papillary renal cell carcinomas.
Zhu, Bin; Poeta, Maria Luana; Costantini, Manuela; Zhang, Tongwu; Shi, Jianxin; Sentinelli, Steno; Zhao, Wei; Pompeo, Vincenzo; Cardelli, Maurizio; Alexandrov, Boian S; Otlu, Burcak; Hua, Xing; Jones, Kristine; Brodie, Seth; Dabrowska, Malgorzata Ewa; Toro, Jorge R; Yeager, Meredith; Wang, Mingyi; Hicks, Belynda; Alexandrov, Ludmil B; Brown, Kevin M; Wedge, David C; Chanock, Stephen; Fazio, Vito Michele; Gallucci, Michele; Landi, Maria Teresa.
Afiliação
  • Zhu B; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, 20892, USA.
  • Poeta ML; Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, 70126, Bari, Italy.
  • Costantini M; Department of Bioscience, Biotechnology and Biopharmaceutics, University of Bari, 70126, Bari, Italy.
  • Zhang T; Department of Urology, "Regina Elena" National Cancer Institute, 00144, Rome, Italy.
  • Shi J; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, 20892, USA.
  • Sentinelli S; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, 20892, USA.
  • Zhao W; Department of Pathology, "Regina Elena" National Cancer Institute, 00144, Rome, Italy.
  • Pompeo V; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, 20892, USA.
  • Cardelli M; Department of Urology, "Regina Elena" National Cancer Institute, 00144, Rome, Italy.
  • Alexandrov BS; Advanced Technology Center for Aging Research, IRCCS INRCA, 60121, Ancona, Italy.
  • Otlu B; Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM, 87545, USA.
  • Hua X; Department of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
  • Jones K; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, 20892, USA.
  • Brodie S; Cancer Genomics Research Laboratory (CGR), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Dabrowska ME; Cancer Genomics Research Laboratory (CGR), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Toro JR; Department of Pathology, "Regina Elena" National Cancer Institute, 00144, Rome, Italy.
  • Yeager M; Laboratory of Molecular Medicine and Biotechnology, University Campus Bio-Medico of Rome, 00128, Rome, Italy.
  • Wang M; Washington, DC Veteran Affairs Medical Center, Washington, DC, 20422, USA.
  • Hicks B; Cancer Genomics Research Laboratory (CGR), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Alexandrov LB; Cancer Genomics Research Laboratory (CGR), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Brown KM; Cancer Genomics Research Laboratory (CGR), Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
  • Wedge DC; Department of Cellular and Molecular Medicine and Department of Bioengineering and Moores Cancer Center, University of California, San Diego, La Jolla, CA, 92093, USA.
  • Chanock S; Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, Bethesda, MD, 20892, USA.
  • Fazio VM; Big Data Institute, Old Road Campus, Oxford, OX3 7LF, UK. david.wedge@manchester.ac.uk.
  • Gallucci M; Oxford NIHR Biomedical Research Centre, Oxford, OX4 2PG, UK. david.wedge@manchester.ac.uk.
  • Landi MT; Manchester Cancer Research Centre, Manchester, M20 4GJ, UK. david.wedge@manchester.ac.uk.
Nat Commun ; 11(1): 3096, 2020 06 18.
Article em En | MEDLINE | ID: mdl-32555180
ABSTRACT
Intratumor heterogeneity (ITH) and tumor evolution have been well described for clear cell renal cell carcinomas (ccRCC), but they are less studied for other kidney cancer subtypes. Here we investigate ITH and clonal evolution of papillary renal cell carcinoma (pRCC) and rarer kidney cancer subtypes, integrating whole-genome sequencing and DNA methylation data. In 29 tumors, up to 10 samples from the center to the periphery of each tumor, and metastatic samples in 2 cases, enable phylogenetic analysis of spatial features of clonal expansion, which shows congruent patterns of genomic and epigenomic evolution. In contrast to previous studies of ccRCC, in pRCC, driver gene mutations and most arm-level somatic copy number alterations (SCNAs) are clonal. These findings suggest that a single biopsy would be sufficient to identify the important genetic drivers and that targeting large-scale SCNAs may improve pRCC treatment, which is currently poor. While type 1 pRCC displays near absence of structural variants (SVs), the more aggressive type 2 pRCC and the rarer subtypes have numerous SVs, which should be pursued for prognostic significance.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma de Células Renais / Neoplasias Renais Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article